Tumour-immune cell interactions modulated by chemokines

Expert Opinion on Biological Therapy

Volumn 8, Issue 3, 2008, Pages 269-290

  Jöhrer, Karin ^a   Pleyer, Lisa ^a,b   Olivier, Angelika ^a   Maizner, Eva ^a   Zelle Rieser, Claudia ^a   Greil, Richard ^a,b  

^a TYROLEAN CANCER RESEARCH INSTITUTE   (Austria)

^b University Hospital Salzburg   (Austria)

Author keywords

Cancer; Chemokine; Chemokine receptor; Immune cells; Immunotherapy

Indexed keywords

1 [5 CHLORO 2 [2 [4 (4 FLUOROBENZYL) 2 METHYL 1 PIPERAZINYL] 2 OXOETHOXY]PHENYL]UREA; APLAVIROC; CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CNTO 888; CP 481 715; CUTANEOUS T CELL ATTRACTING CHEMOKINE; CXCL9 CHEMOKINE; DNA VACCINE; FRACTALKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INCB 3282; INCB 3284; INTERLEUKIN 12; INTERLEUKIN 2; KW 0761; LYMPHOTACTIN; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; MARAVIROC; MK 0812; MONOCLONAL ANTIBODY CCL2; MONOCLONAL ANTIBODY CCR4; PLERIXAFOR; PRO 140; RANTES; SECONDARY LYMPHOID TISSUE CHEMOKINE; T 140; THYMUS AND ACTIVATION REGULATED CHEMOKINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VICRIVIROC;

ALLERGY; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; BREAST CANCER; BREAST CARCINOMA; CANCER GROWTH; CANCER IMMUNOTHERAPY; CELL INFILTRATION; CELL INTERACTION; CELL MATURATION; CELL MIGRATION; CELL SURVIVAL; CLINICAL TRIAL; COLON CARCINOMA; COMBINATION CHEMOTHERAPY; CROHN DISEASE; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG POTENTIATION; EOSINOPHIL; FIBROSARCOMA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IMMUNOSURVEILLANCE; LIVER CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG CANCER; LYMPHOMA; MACROPHAGE; MONOTHERAPY; MULTIPLE MYELOMA; MULTIPLE SCLEROSIS; MYELOMA; NATURAL KILLER CELL; NEOPLASM; NEUROBLASTOMA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CARCINOMA; PANNICULITIS; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; T CELL LEUKEMIA; T LYMPHOCYTE; THYMOMA; TUMOR IMMUNITY;

ANIMALS; CELL COMMUNICATION; CHEMOKINES; DISEASE MODELS, ANIMAL; HUMANS; NEOPLASMS; RECEPTORS, CHEMOKINE;

MURINAE;

EID: 41149135626     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.8.3.269     Document Type: Review

References (163)

1. Imaizumi A, Torisu M, Yoshida T. A chemotactic factor for rat thymocytes may regulate T-lymphocyte migration toward the thymic microenvironment. Cell Immunol 1987;108(1):53-63
2. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420(6917):860-7
3. Baggiolini M. Chemokines and leukocyte traffic. Nature 1998;392(6676):565-8
4. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer 2004;4(7):540-50
5. Rossi D, Zlotnik A. The biology of chemokines and their receptors. Ann Rev Immunol 2000:18217-42
6. Balabanian K, Lagane B, Infantino S, et al. The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. J Biol Chem 2005;280(42):35760-6
7. Petkovic V, Moghini C, Paoletti S, et al. I-TAC/CXCL11 is a natural antagonist for CCR5. J Leukoc Biol 2004;76(3):701-8
8. Petkovic V, Moghini C, Paoletti S, et al. Eotaxin-3/CCL26 is a natural antagonist for CC chemokine receptors 1 and 5. A human chemokine with a regulatory role. J Biol Chem 2004;279(22):23357-63
9. Loetscher P, Pellegrino A, Gong JH, et al. The ligands of CXC chemokine receptor 3, I-TAC, Mig, and IP10, are natural antagonists for CCR3. J Biol Chem 2001;276(5):2986-91
10. Hadley TJ, Peiper SC. From malaria to chemokine receptor: the emerging physiologic role of the Duffy blood group antigen. Blood 1997;89(9):3077-91
11. Nibbs RJ, Wylie SM, Yang J, et al. Cloning and characterization of a novel promiscuous human β-chemokine receptor D6. J Biol Chem 1997;272(51):32078-83
12. Ali H, Richardson RM, Haribabu B, Snyderman R. Chemoattractant receptor cross-desensitization. J Biol Chem 1999;274(10):6027-30
13. Kurt RA, Baher A, Wisner KP, et al. Chemokine receptor desensitization in tumor-bearing mice. Cell Immunol 2001;207(2):81-8
14. Dragic T, Litwin V, Allaway GP, et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996;381(6584):667-73
15. Gershengorn MC, Geras-Raaka E, Varma A, Clark-Lewis I. Chemokines activate Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor in mammalian cells in culture. J Clin Invest 1998;102(8):1469-72
16. Rot A, Von Andrian UH. Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Ann Rev Immunol 2004;22891-928 •• Comprehensive review on chemokines.
17. Zlotnik A, Yoshie O, Nomiyama H. The chemokine and chemokine receptor superfamilies and their molecular evolution. Genome Biol 2006;7(12):243
18. Tachibana K, Hirota S, Iizasa H, et al. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature 1998;393(6685):591-4
19. Palczewski K, Kumasaka T, Hori T, et al. Crystal structure of rhodopsin: a G protein-coupled receptor. Science 2000;289(5480):739-45
20. Thelen M. Dancing to the tune of chemokines. Nat Immunol 2001;2(2):129-34
21. Rodriguez-Frade JM, Mellado M, Martinez A. Chemokine receptor dimerization: two are better than one. Trends Immunol 2001;22(11):612-7
22. Vlahakis SR, Villasis-Keever A, Gomez T, et al. G protein-coupled chemokine receptors induce both survival and apoptotic signaling pathways. J Immunol 2002;169(10):5546-54 •• Interesting dissection of receptor signalling.
23. Tanaka Y, Adams DH, Hubscher S, et al. T-cell adhesion induced by proteoglycanimmobilized cytokine MIP-1β. Nature 1993;361(6407):79-82
24. Rot A. Endothelial cell binding of NAP-1/IL-8: role in neutrophil emigration. Immunol Today 1992;13(8):291-4
25. Appay V, Rowland-Jones SL. Rantes: a versatile and controversial chemokine. Trends Immunol 2001;22(2):83-7
26. Johnson Z, Proudfoot AE, Handel TM. Interaction of chemokines and glycosaminoglycans: a new twist in the regulation of chemokine function with opportunities for therapeutic intervention. Cytokine Growth Factor Rev 2005;16(6):625-36 • Shows new possibilities for manipulation of chemokine action.
27. Potzinger H, Geretti E, Brandner B, et al. Developing chemokine mutants with improved proteoglycan affinity and knocked-out GPCR activity as anti-inflammatory recombinant drugs. Biochem Soc Trans 2006;34(Pt 3):435-7
28. Kohrgruber N, Groger M, Meraner P, et al. Plasmacytoid dendritic cell recruitment by immobilized CXCR3 ligands. J Immunol 2004;173(11):6592-602
29. Poznansky MC, Olszak IT, Foxall R, et al. Active movement of T cells away from a chemokine. Nat Med 2000;6(5):543-8
30. Ogilvie P, Paoletti S, Clark-Lewis I, Uguccioni M. Eotaxin-3 is a natural antagonist for CCR2 and exerts a repulsive effect on human monocytes. Blood 2003;102(3):789-94
31. Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001;410(6824):50-6
32. Schutyser E, Su Y, Yu Y, et al. Hypoxia enhances CXCR4 expression in human microvascular endothelial cells and human melanoma cells. Eur Cytokine Netw 2007;18(2):59-70
33. Burger JA, Tsukada N, Burger M, et al. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 2000;96(8):2655-63
34. Sun YX, Wang J, Shelburne CE, et al. Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J Cell Biochem 2003;89(3):462-73
35. Bian XW, Yang SX, Chen JH, et al. Preferential expression of chemokine receptor CXCR4 by highly malignant human gliomas and its association with poor patient survival. Neurosurgery 2007;61(3):570-8
36. Hideshima T, Chauhan D, Hayashi T, et al. The biological sequelae of stromal cell-derived factor-1α in multiple myeloma. Mol Cancer Ther 2002;1(7):539-44
37. Johrer K, Janke K, Krugmann J, et al. Transendothelial migration of myeloma cells is increased by TNF-a via TNF-R2 and autocrine upregulation of MCP-1. Clin Cancer Res 2004;10(6):1901-10
38. Craig MJ, Loberg RD. CCL2 (Monocyte Chemoattractant Protein-1) in cancer bone metastases. Cancer Metastasis Rev 2006;25(4):611-9
39. Kleinhans M, Tun-Kyi A, Gilliet M, et al. Functional expression of the eotaxin receptor CCR3 in CD30+ cutaneous T-cell lymphoma. Blood 2003;101(4):1487-93
40. Ishida T, Utsunomiya A, Iida S, et al. Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome. Clin Cancer Res 2003;9(10 Pt 1):3625-34
41. Seidl H, Richtig E, Tilz H, et al. Profiles of chemokine receptors in melanocytic lesions: de novo expression of CXCR6 in melanoma. Hum Pathol 2007;38(5):768-80
42. Zlotnik A. Chemokines and cancer. Int J Cancer 2006;119(9):2026-9
43. Singh S, Sadanandam A, Singh RK. Chemokines in tumor angiogenesis and metastasis. Cancer Metastasis Rev 2007;26(3-4):453-67
44. Strieter RM, Burdick MD, Mestas J, et al. Cancer CXC chemokine networks and tumour angiogenesis. Eur J Cancer 2006;42(6):768-78
45. Zhu YM, Woll PJ. Mitogenic effects of interleukin-8/CXCL8 on cancer cells. Future Oncol 2005;1(5):699-704
46. Johrer K, Zelle-Rieser C, Perathoner A, et al. Up-regulation of functional chemokine receptor CCR3 in human renal cell carcinoma. Clin Cancer Res 2005;11(7):2459-65
47. Kleeff J, Kusama T, Rossi DL, et al. Detection and localization of Mip-3α/LARC/Exodus, a macrophage proinflammatory chemokine, and its CCR6 receptor in human pancreatic cancer. Int J Cancer 1999;81(4):650-7
48. Giuliani N, Bonomini S, Romagnani P, et al. CXCR3 and its binding chemokines in myeloma cells: expression of isoforms and potential relationships with myeloma cell proliferation and survival. Haematologica 2006;91(11):1489-97
49. Addison CL, Arenberg DA, Morris SB, et al. The CXC chemokine, monokine induced by interferon-gamma, inhibits non-small cell lung carcinoma tumor growth and metastasis. Hum Gene Ther 2000;11(2):247-61
50. Zipin-Roitman A, Meshel T, Sagi-Assif O, et al. CXCL10 promotes invasion-related properties in human colorectal carcinoma cells. Cancer Res 2007;67(7):3396-405
51. Robledo MM, Bartolome RA, Longo N, et al. Expression of functional chemokine receptors CXCR3 and CXCR4 on human melanoma cells. J Biol Chem 2001;276(48):45098-105
52. Kucia M, Reca R, Miekus K, et al. Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem Cells 2005;23(7):879-94
53. Wysoczynski M, Reca R, Ratajczak J, et al. Incorporation of CXCR4 into membrane lipid rafts primes homing-related responses of hematopoietic stem/progenitor cells to an SDF-1 gradient. Blood 2005;105(1):40-8
54. Mocellin S, Nitti D. Therapeutics targeting tumor immune escape: towards the development of new generation anticancer vaccines. Med Res Rev 2007;In Press
55. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348(3):203-13
56. Hojo S, Koizumi K, Tsuneyama K, et al. High-level expression of chemokine CXCL16 by tumor cells correlates with a good prognosis and increased tumor-infiltrating lymphocytes in colorectal cancer. Cancer Res 2007;67(10):4725-31
57. Kondo T, Ito F, Nakazawa H, et al. High expression of chemokine gene as a favorable prognostic factor in renal cell carcinoma. J Urol 2004;171(6 Pt 1):2171-5
58. Kondo T, Nakazawa H, Ito F, et al. Favorable prognosis of renal cell carcinoma with increased expression of chemokines associated with a Th1-type immune response. Cancer Sci 2006;97(8):780-6
59. Monti P, Leone BE, Marchesi F, et al. The CC chemokine MCP-1/CCL2 in pancreatic cancer progression: regulation of expression and potential mechanisms of antimalignant activity. Cancer Res 2003;63(21):7451-61
60. Moran CJ, Arenberg DA, Huang CC, et al. RANTES expression is a predictor of survival in stage I lung adenocarcinoma. Clin Cancer Res 2002;8(12):3803-12
61. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3(11):991-8 • Interesting theory on immune escape of cancers.
62. Marrogi AJ, Munshi A, Merogi AJ, et al. Study of tumor infiltrating lymphocytes and transforming growth factor-β as prognostic factors in breast carcinoma. Int J Cancer 1997;74(5):492-501
63. Naito Y, Saito K, Shiiba K, et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 1998;58(16):3491-4
64. Schumacher K, Haensch W, Roefzaad C, Schlag PM. Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. Cancer Res 2001;61(10):3932-6
65. Tinhofer I, Rubenzer G, Holler C, et al. Expression levels of CD38 in T cells predict course of disease in male patients with B-chronic lymphocytic leukemia. Blood 2006;108(9):2950-6
66. Mantovani A, Schioppa T, Porta C, et al. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev 2006;25(3):315-22
67. Vicari AP, Caux C. Chemokines in cancer. Cytokine Growth Factor Rev 2002;13(2):143-54
68. Luboshits G, Shina S, Kaplan O, et al. Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma. Cancer Res 1999;59(18):4681-7
69. Robinson SC, Scott KA, Balkwill FR. Chemokine stimulation of monocyte matrix metalloproteinase-9 requires endogenous TNF-α. Eur J Immunol 2002;32(2):404-12
70. Ghilardi G, Biondi ML, La TA, Battaglioli L, Scorza R. Breast cancer progression and host polymorphisms in the chemokine system: role of the macrophage chemoattractant protein-1 (MCP-1) -2518 G allele. Clin Chem 2005;51(2):452-5
71. Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 2002;196(3):254-65
72. Kalinski P, Giermasz A, Nakamura Y, et al. Helper role of NK cells during the induction of anticancer responses by dendritic cells. Mol Immunol 2005;42(4):535-9
73. Epling-Burnette PK, Bai F, Painter JS, et al. Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors. Blood 2007;109(11):4816-24
74. Esendagli G, Bruderek K, Goldmann T, et al. Malignant and non-malignant lung tissue areas are differentially populated by natural killer cells and regulatory T cells in non-small cell lung cancer. Lung Cancer 2008;59(1):32-40
75. Jurisic V, Srdic T, Konjevic G, et al. Clinical stage-depending decrease of NK cell activity in multiple myeloma patients. Med. Oncol. 200724(3):312-317.
76. Bamias A, Tsiatas ML, Kafantari E, et al. Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3+CD56+ cells with platinum resistance. Gynecol Oncol 2007;106(1):75-81
77. Taieb J, Chaput N, Menard C, et al. A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med 2006;12(2):214-9
78. Ullrich E, Bonmort M, Mignot G, et al. Therapy-induced tumor immunosurveillance involves IFN-producing killer dendritic cells. Cancer Res 2007;67(3):851-3
79. Xin H, Kikuchi T, Andarini S, et al. Antitumor immune response by CX3CL1 fractalkine gene transfer depends on both NK and T cells. Eur J Immunol 2005;35(5):1371-80
80. Starnes T, Rasila KK, Robertson MJ, et al. The chemokine CXCL14 (BRAK) stimulates activated NK cell migration: implications for the downregulation of CXCL14 in malignancy. Exp Hematol 2006;34(8):1101-5
81. Shellenberger TD, Wang M, Gujrati M, et al. BRAK/CXCL14 is a potent inhibitor of angiogenesis and a chemotactic factor for immature dendritic cells. Cancer Res 2004;64(22):8262-70
82. Roda JM, Parihar R, Magro C, et al. Natural killer cells produce T cell-recruiting chemokines in response to antibody-coated tumor cells. Cancer Res 2006;66(1):517-26
83. Lanzavecchia A, Sallusto F. Regulation of T cell immunity by dendritic cells. Cell 2001;106(3):263-6
84. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 2007;449(7161):419-26
85. Zou W, Machelon V, Coulomb-L'Hermin A, et al. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med 2001;7(12):1339-46
86. Vanbervliet B, Driss-Vermare N, Massacrier C, et al. The inducible CXCR3 ligands control plasmacytoid dendritic cell responsiveness to the constitutive chemokine stromal cell-derived factor 1 (SDF-1)/CXCL12. J Exp Med 2003;198(5):823-30
87. Curiel TJ, Cheng P, Mottram P, et al. Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer. Cancer Res 2004;64(16):5535-8
88. D'Amico G, Frascaroli G, Bianchi G, et al. Uncoupling of inflammatory chemokine receptors by IL-10: generation of functional decoys. Nat Immunol 2000;1(5):387-91
89. Feijoo E, Alfaro C, Mazzolini G, et al. Dendritic cells delivered inside human carcinomas are sequestered by interleukin-8. Int J Cancer 2005;116(2):275-81
90. Frederick MJ, Clayman GL. Chemokines in cancer. Expert Rev Mol Med 2001;3(19):18-31
91. Shurin GV, Ferris RL, Tourkova IL, et al. Loss of new chemokine CXCL14 in tumor tissue is associated with low infiltration by dendritic cells (DC), while restoration of human CXCL14 expression in tumor cells causes attraction of DC both in vitro and in vivo. J Immunol 2005;174(9):5490-8
92. Omata N, Yasutomi M, Yamada A, et al. Monocyte chemoattractant protein-1 selectively inhibits the acquisition of CD40 ligand-dependent IL-12-producing capacity of monocyte-derived dendritic cells and modulates Th1 immune response. J Immunol 2002;169(9):4861-6
93. Remmel E, Terracciano L, Noppen C, et al. Modulation of dendritic cell phenotype and mobility by tumor cells in vitro. Hum Immunol 2001;62(1):39-49
94. Dell'Agnola C, Biragyn A. Clinical utilization of chemokines to combat cancer: the double-edged sword. Expert Rev Vaccines 2007;6(2):267-83 • Excellent review on chemokines in cancer therapy.
95. Shurin MR, Shurin GV, Lokshin A, et al. Intratumoral cytokines/ chemokines/growth factors and tumor infiltrating dendritic cells: friends or enemies? Cancer Metastasis Rev 2006;25(3):333-56
96. Peng L, Shu S, Krauss JC. Monocyte chemoattractant protein inhibits the generation of tumor-reactive T cells. Cancer Res 1997;57(21):4849-54
97. Luther SA, Cyster JG. Chemokines as regulators of T cell differentiation. Nar Immunol 2001;2(2):102-7
98. Karpus WJ, Lukacs NW, Kennedy KJ, et al. Differential CC chemokine-induced enhancement of T helper cell cytokine production. J Immunol 1997;158(9):4129-36
99. Cridge TJ, Horowitz KM, Marinucci MN, et al. Functional and molecular alterations in T Cells induced by CCL5. Immunol Invest 2006;35(1):115-32
100. Adler ER Lemken CA, Katchen NS, Kurt RA. A dual role for tumor-derived chemokine RANTES (CCL5). Immunol Lett 2003;90(2-3):187-94
101. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10(9):942-9
102. Ishida T, Ueda R. CCR4 as a novel molecular target for immunotherapy of cancer. Cancer Sci 2006;97(11):1139-46
103. Romagnani P, Maggi L, Mazzinghi B, et al. CXCR3-mediated opposite effects of CXCL10 and CXCL4 on TH1 or TH2 cytokine production. J Allergy Clin Immunol 2005;116(6):1372-9
104. Dufour JH, Dziejman M, Liu MT, et al. IFN-γ-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J Immunol 2002;168(7):3195-204
105. Heller EA, Liu E, Tager AM, et al. Chemokine CXCL10 promotes atherogenesis by modulating the local balance of effector and regulatory T cells. Circulation 2006;113(19):2301-12
106. Luster AD, Leder P. IP-10, a -C-X-C-chemokine, elicits a potent thymus-dependent antitumor response in vivo. J Exp Med 1993;178(3):1057-65
107. Liu YQ, Poon RT, Hughes J, et al. Desensitization of T lymphocyte function by CXCR3 ligands in human hepatocellular carcinoma. World J Gastroenterol 2005;11(2):164-70
108. Winter D, Moser J, Kriehuber E, et al. Down-modulation of CXCR3 surface expression and function in CD8+ T cells from cutaneous T cell lymphoma patients. J Immunol 2007;179(6):4272-82
109. Kataoka S, Konishi Y, Nishio Y. Antitumor activity of eosinophils activated by IL-5 and eotaxin against hepatocellular carcinoma. DNA Cell Biol 2004;23(9):549-60
110. Hanamoto H, Nakayama T, Miyazato H, et al. Expression of CCL28 by Reed-Sternberg cells defi nes a major subtype of classical Hodgkin's disease with frequent infi ltration of eosinophils and/or plasma cells. Am J Pathol 2004;164 (3):997-1006
111. Simson L, Ellyard JI, Dent LA, et al. Regulation of carcinogenesis by IL-5 and CCL11: a potential role for eosinophils in tumor immune surveillance. J Immunol 2007;178(7):4222-9
112. Kadin M, Butmarc J, Elovic A, Wong D. Eosinophils are the major source of transforming growth factor-β 1 in nodular sclerosing Hodgkin's disease. Am J Pathol 1993;142(1):11-6
113. Liu LY, Bates ME, Jarjour NN, et al. Generation of Th1 and Th2 chemokines by human eosinophils: evidence for a critical role of TNF-α. J Immunol 2007;179(7):4840-8
114. Mule JJ, Custer M, Averbook B, et al. RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: role of immune cell subpopulations. Hum Gene Ther 1996;7(13):1545-53
115. Crittenden M, Gough M, Harrington K, et al. Expression of inflammatory chemokines combined with local tumor destruction enhances tumor regression and long-term immunity. Cancer Res 2003;63(17):5505-12
116. Braun SE, Chen K, Foster RG, et al. The CC chemokine CKβ-11/MIP- 3β/ELC/Exodus 3 mediates tumor rejection of murine breast cancer cells through NK cells. J Immunol 2000;164(8):4025-31
117. Vicari AP, It-Yahia S, Chemin K, et al. Antitumor effects of the mouse chemokine 6Ckine/SLC through angiostatic and immunological mechanisms. J Immunol 2000;165(4):1992-2000
118. Guiducci C, Di CE, Parenza M, et al. Intralesional injection of adenovirus encoding CC chemokine ligand 16 inhibits mammary tumor growth and prevents metastatic-induced death after surgical removal of the treated primary tumor. J Immunol 2004;172(7):4026-36
119. Kanagawa N, Niwa M, Hatanaka Y, et al. CC-chemokine ligand 17 gene therapy induces tumor regression through augmentation of tumor-infiltrating immune cells in a murine model of preexisting CT26 colon carcinoma. Int J Cancer 2007;121(9):2013-22
120. Chu Y, Yang X, Xu W, et al. In situ expression of IFN-γ-inducible T cell α chemoattracrant in breast cancer mounts an enhanced specific anti-tumor immunity which leads to tumor regression. Cancer Immunol Immunother 2007;56(10):1539-49
121. Hisada M, Yoshimoto T, Kamiya S, et al. Synergistic antitumor effect by coexpression of chemokine CCL21/SLC and costimulatory molecule LIGHT. Cancer Gene Ther 2004;11(4):280-8
122. Gao JQ, Kanagawa N, Motomura Y, et al. Cotransduction of CCL27 gene can improve the efficacy and safety of IL-12 gene therapy for cancer. Gene Ther 2007;14(6):491-502
123. Pertl U, Luster AD, Varki NM, et al. IFN-γ-inducible protein-10 is essential for the generation of a protective tumor-specific CD8 T cell response induced by single-chain IL-12 gene therapy. J Immunol 2001;166(11):6944-51
124. Rousseau RF, Haight AE, Hirschmann-Jax C, et al. Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma. Blood 2003;101(5):1718-26
125. Russell HV, Strother D, Mei Z, et al. Phase I trial of vaccination with autologous neuroblastoma tumor cells genetically modified to secrete IL-2 and lymphotactin. J Immunother 2007;30(2):227-33
126. Liang CM, Ye SL, Zhong CP, et al. More than chemotaxis: a new anti-tumor DC vaccine modified by rAAV2-SLC. Mol Immunol 2007;44(15):3797-804
127. Westermann J, Nguyen-Hoai T, Baldenhofer G, et al. CCL19 (ELC) as an adjuvant for DNA vaccination: induction of a TH1-type T-cell response and enhancement of antitumor immunity. Cancer Gene Ther 2007;14(6):523-32
128. Yang SC, Hillinger S, Riedl K, et al. Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity. Clin Cancer Res 2004;10(8):2891-901
129. Terando A, Roessler B, Mule JJ. Chemokine gene modification of human dendritic cell-based tumor vaccines using a recombinant adenoviral vector. Cancer Gene Ther 2004;11(3):165-73
130. Biragyn A, Ruffini PA, Coscia M, et al. Chemokine receptor-mediated delivery directs self-tumor antigen efficiently into the class II processing pathway in vitro and induces protective immunity in vivo. Blood 2004;104(7):1961-9 •• Interesting approach to specifically target potent immune cells to tumour cells.
131. Schiavo R, Baatar D, Olkhanud P, et al. Chemokine receptor targeting efficiently directs antigens to MHC class I pathways and elicits antigen-specific CD8+ T-cell responses. Blood 2006;107(12):4597-605
132. Marin V, Kakuda H, Dander E, et al. Enhancement of the anti-leukemic activity of cytokine induced killer cells with an anti-CD 19 chimeric receptor delivering a 4-1BB-ζ activating signal. Exp Hematol 2007;35(9):1388-97
133. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353(16):1659-72
134. D'Elios MM, Amedei A, Cappon A, et al. The neutrophil-activating protein of Helicobacter pylori (HP-NAP) as an immune modulating agent. FEMS Immunol Med Microbiol 2007;50(2):157-64
135. Amedei A, Cappon A, Codolo G, et al. The neutrophil-activating protein of Helicobacter pylori promotes Th1 immune responses. J Clin Invest 2006;116(4):1092-101
136. Rathinavelu S, Kao JY, Zavros Y, Merchant JL. Helicobacter pylori outer membrane protein 18 (Hp1125) induces dendritic cell maturation and function. Helicobacter 2005;10(5):424-32
137. Correa P, Houghton J. Carcinogenesis of Helicobacter pylori. Gastroenterology 2007;133(2):659-72
138. Loberg RD, Ying C, Craig M, et al. Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. Cancer Res 2007;67(19):9417-24
139. Reali E, Spisani S, Gavioli R, et al. IL-8 enhances antibody-dependent cellular cytotoxicity in human neutrophils. Immunol Cell Biol 1995;73(3):234-8
140. Dehqanzada ZA, Storrer CE, Hueman MT, et al. Correlations between serum monocyte chemotactic protein-1 levels, clinical prognostic factors, and HER-2/neu vaccine-related immunity in breast cancer patients. Clin Cancer Res 2006;12(2):478-86
141. Lavergne E, Combadiere C, Iga M, et al. Intratumoral CC chemokine ligand 5 overexpression delays tumor growth and increases tumor cell infiltration. J Immunol 2004;173(6):3755-62
142. Lee JM, Merritt RE, Mahtabifard A, et al. Intratumoral expression of macrophage-derived chemokine induces CD4+ T cell-independent antitumor immunity in mice. J Immunother 2003;26(2):117-29
143. Guo J, Chen T, Wang B, et al. Chemoattraction, adhesion and activation of natural killer cells are involved in the antitumor immune response induced by fractalkine/CX3CL1. Immunol Lett 2003;89(1):1-7
144. Palmer K, Hitt M, Emtage PC, et al. Combined CXC chemokine and interleukin-12 gene transfer enhances antitumor immunity. Gene Ther 2001;8(4):282-90
145. Zeng Y, Huebener N, Fest S, et al. Fractalkine (CX3CL1)- and interleukin-2-enriched neuroblastoma microenvironment induces eradication of metastases mediated by T cells and natural killer cells. Cancer Res 2007;67(5):2331-8
146. Yang SC, Hillinger S, Riedl K, et al. Intratumoral adminisrration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity. Clin Cancer Res 2004;10(8):2891-901
147. Redondo-Munoz J, Terol MJ, Garcia-Marco JA, Garcia-Pardo A. MMP-9 is upregulated by CCL21/CCR7 interaction via ERK1/2 signaling and is involved in CCL21-driven B-CLL cell invasion and migration. Blood 2008;111(1):383-6
148. Chunsong H, Yuling H, Li W, et al. CXC chemokine ligand 13 and CC chemokine ligand 19 cooperatively render resistance to apoptosis in B cell lineage acute and chronic lymphocytic leukemia CD23+CD5+ B cells. J Immunol 2006;177(10):6713-22
149. Ticchioni M, Essafi M, Jeandel PY, et al. Homeostatic chemokines increase survival of B-chronic lymphocytic leukemia cells through inactivation of transcription factor FOXO3a. Oncogene 2007;26(50):7081-91
150. Burkle A, Niedermeier M, Schmitt-Graff A, et al. Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B cell chronic lymphocytic leukemia. Blood 2007;110(9):3316-25
151. Kawada K, Sonoshita M, Sakashita H, et al. Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes. Cancer Res 2004;64(11):4010-7
152. Kawada K, Hosogi H, Sonoshita M, et al. Chemokine receptor CXCR3 promotes colon cancer metastasis to lymph nodes. Oncogene 2007;26(32):4679-88
153. Juarez J, Baraz R, Gaundar S, et al. Interaction of interleukin-7 and interleukin-3 with the CXCL12-induced proliferation of B-cell progenitor acute lymphoblastic leukemia. Haematologica 2007;92(4):450-9
154. Epstein RJ. The CXCL12-CXCR4 chemotactic pathway as a target of adjuvant breast cancer therapies. Nat Rev Cancer 2004;4(11):901-9
155. Ao M, Franco OE, Park D, et al. Cross-talk between paracrine-acting cytokine and chemokine pathways promotes malignancy in benign human prostatic epithelium. Cancer Res 2007;67(9):4244-53
156. Juarez J, Dela PA, Baraz R, et al. CXCR4 antagonists mobilize childhood acute lymphoblastic leukemia cells into the peripheral blood and inhibit engraftment. Leukemia 2007;21(6):1249-57
157. Liang Z, Yoon Y, Votaw J, et al. Silencing of CXCR4 blocks breast cancer metastasis. Cancer Res 2005;65(3):967-71
158. Lapteva N, Yang AG, Sanders DE, et al. CXCR4 knockdown by small interfering RNA abrogates breast tumor growth in vivo. Cancer Gene Ther 2005;12(1):84-9
159. Gulick RM, Su Z, Flexner C, et al. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211. J Infect Dis 2007;196(2):304-12
160. Murga JD, Franti M, Pevear DC, et al. Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1. Antimicrob Agents Chemother 2006;50(10):3289-96
161. Borczuk AC, Papanikolaou N, Toonkel RL, et al. Lung adenocarcinoma invasion in TGFβRII-deficient cells is mediated by CCL5/RANTES. Oncogene 2007;27(4):557-64
162. Loberg RD, Ying C, Craig M, et al. Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. Cancer Res 2007;67(19):9417-24
163. Vanderkerken K, Broek IV, Eizirik DL, et al. Monocyte chemoattractant protein-1 (MCP-1), secreted by bone marrow endothelial cells, induces chemoattraction of 5T multiple myeloma cells. Clin Exp Metastasis 2002;19(1):87-90